JPH0322372B2 - - Google Patents
Info
- Publication number
- JPH0322372B2 JPH0322372B2 JP57118968A JP11896882A JPH0322372B2 JP H0322372 B2 JPH0322372 B2 JP H0322372B2 JP 57118968 A JP57118968 A JP 57118968A JP 11896882 A JP11896882 A JP 11896882A JP H0322372 B2 JPH0322372 B2 JP H0322372B2
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- fatty acid
- present
- composition
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000014150 Interferons Human genes 0.000 claims description 46
- 108010050904 Interferons Proteins 0.000 claims description 46
- 229940079322 interferon Drugs 0.000 claims description 42
- -1 polyoxyethylene Polymers 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 23
- 239000000693 micelle Substances 0.000 claims description 20
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 14
- 239000000194 fatty acid Substances 0.000 claims description 14
- 229930195729 fatty acid Natural products 0.000 claims description 14
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 8
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 229940051841 polyoxyethylene ether Drugs 0.000 claims description 7
- 229920000056 polyoxyethylene ether Polymers 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000000243 solution Substances 0.000 description 23
- 239000000843 powder Substances 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 210000002429 large intestine Anatomy 0.000 description 5
- 210000004880 lymph fluid Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 4
- 239000005642 Oleic acid Substances 0.000 description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 229940047124 interferons Drugs 0.000 description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
- 102000006992 Interferon-alpha Human genes 0.000 description 3
- 108010047761 Interferon-alpha Proteins 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000002751 lymph Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000006215 rectal suppository Substances 0.000 description 2
- 229940100618 rectal suppository Drugs 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- ONAIRGOTKJCYEY-XXDXYRHBSA-N CCCCCCCCCCCCCCCCCC(O)=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ONAIRGOTKJCYEY-XXDXYRHBSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57118968A JPS5910524A (ja) | 1982-07-08 | 1982-07-08 | インタ−フエロン組成物およびその製造法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57118968A JPS5910524A (ja) | 1982-07-08 | 1982-07-08 | インタ−フエロン組成物およびその製造法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5910524A JPS5910524A (ja) | 1984-01-20 |
| JPH0322372B2 true JPH0322372B2 (enrdf_load_stackoverflow) | 1991-03-26 |
Family
ID=14749733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57118968A Granted JPS5910524A (ja) | 1982-07-08 | 1982-07-08 | インタ−フエロン組成物およびその製造法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5910524A (enrdf_load_stackoverflow) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0211835B1 (en) * | 1984-03-28 | 1990-01-03 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
| JPS61277633A (ja) * | 1985-05-31 | 1986-12-08 | Toray Ind Inc | インタ−フエロン組成物 |
| JPS6233128A (ja) * | 1985-08-07 | 1987-02-13 | Toray Ind Inc | インタ−フエロン腸溶性経口用製剤 |
| JPS62185030A (ja) * | 1986-02-07 | 1987-08-13 | Toray Ind Inc | 経鼻投与用インタ−フエロン製剤 |
| JPS62283934A (ja) * | 1986-06-02 | 1987-12-09 | Bitamin Kenkyusho:Kk | インタ−フエロン包埋リポソ−ム製剤 |
| JP2577742B2 (ja) * | 1986-07-18 | 1997-02-05 | 中外製薬株式会社 | 安定な顆粒球コロニ−刺激因子含有製剤 |
| CA1294215C (en) * | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| US5183746A (en) * | 1986-10-27 | 1993-02-02 | Schering Aktiengesellschaft | Formulation processes for pharmaceutical compositions of recombinant β- |
| GB8630273D0 (en) * | 1986-12-18 | 1987-01-28 | Til Medical Ltd | Pharmaceutical delivery systems |
| DE3731255A1 (de) * | 1987-09-17 | 1989-04-06 | Boehringer Ingelheim Int | Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen |
| US5004605A (en) * | 1987-12-10 | 1991-04-02 | Cetus Corporation | Low pH pharmaceutical compositions of recombinant β-interferon |
| JPH0651642B2 (ja) * | 1988-11-14 | 1994-07-06 | 大塚製薬株式会社 | インターフェロン経鼻投与用製剤 |
-
1982
- 1982-07-08 JP JP57118968A patent/JPS5910524A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5910524A (ja) | 1984-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69713378T2 (de) | Stabile protein- und nukleinsäure- formulierungen unter verwendung nichtwässriger, wasserfreier, aprotischer, hydrophober, nichtpolarer vehikel mit geringer reaktivität | |
| US6180096B1 (en) | Formulations for protection of peg-interferon alpha conjugates | |
| JPH0322372B2 (enrdf_load_stackoverflow) | ||
| JPH03503764A (ja) | ヒト成長ホルモン製剤 | |
| JPS5885813A (ja) | 吸収性良好な製剤 | |
| JPS61194034A (ja) | 経鼻投与用粉末状組成物 | |
| DE3486029T2 (de) | Ifn-praeparat mit verzoegerter abgabe fuer parentale verabreichung. | |
| JPS61246134A (ja) | 腸管吸収化合物および複合体 | |
| CA2324467C (en) | Formulations for protection of peg-interferon alpha conjugates | |
| JPH0597694A (ja) | 生理活性ペプチド製剤 | |
| JPH0278699A (ja) | ベンゾイルウレア系化合物・アルブミン複合体 | |
| JPH02213A (ja) | 生理活性ペプチド持続製剤 | |
| WO1996020001A1 (fr) | Preparation traversant la muqueuse | |
| JPS58162517A (ja) | 脂溶性ビタミン含有脂肪乳剤 | |
| JPS6345366B2 (enrdf_load_stackoverflow) | ||
| JPH0512328B2 (enrdf_load_stackoverflow) | ||
| JPH0372046B2 (enrdf_load_stackoverflow) | ||
| JPS59181223A (ja) | インタ−フエロンの安定化法 | |
| JPS6233128A (ja) | インタ−フエロン腸溶性経口用製剤 | |
| RU2022128012A (ru) | Жидкие составы белков, содержащие средства для снижения вязкости | |
| KR930002093B1 (ko) | 단백질 의약품의 경구투여용 조성물 | |
| JPH0242809B2 (enrdf_load_stackoverflow) | ||
| JPS6277333A (ja) | インタ−フエロン坐薬製剤 | |
| JPH03106821A (ja) | 抗腫瘍剤 | |
| JPH05238949A (ja) | 注射用組成物 |